Sparsentan Versus Irbesartan in Pediatric Patients With FSGS
Introduction: Sparsentan, a nonimmunosuppressive dual endothelin angiotensin receptor antagonist, led to rapid and sustained proteinuria reductions versus maximum labeled dose irbesartan in patients with focal segmental glomerulosclerosis (FSGS) in the phase 3 DUPLEX trial (NCT03493685). Here, we de...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2026-07-01
|
| Seri Bilgileri: | Kidney International Reports |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2468024926027981 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|